215 related articles for article (PubMed ID: 20870446)
41. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia.
Goldman JG; Stebbins GT; Bernard B; Stoub TR; Goetz CG; deToledo-Morrell L
Mov Disord; 2012 May; 27(6):727-34. PubMed ID: 22410753
[TBL] [Abstract][Full Text] [Related]
42. Freezing of gait in Parkinson's disease: functional neuroimaging studies of the frontal lobe.
Gallardo MJ; Cabello JP; Corrales MJ; Torres-Donaire J; Bravo JJ; Talavera MP; León A; Vaamonde-Gamo J
Neurol Res; 2018 Oct; 40(10):900-905. PubMed ID: 29985119
[TBL] [Abstract][Full Text] [Related]
43. Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimer's Disease and Parkinson's Disease Dementia?
Femminella GD; Ninan S; Atkinson R; Fan Z; Brooks DJ; Edison P
J Alzheimers Dis; 2016; 51(4):1275-89. PubMed ID: 27060942
[TBL] [Abstract][Full Text] [Related]
44. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study.
Hu MT; Taylor-Robinson SD; Chaudhuri KR; Bell JD; Labbé C; Cunningham VJ; Koepp MJ; Hammers A; Morris RG; Turjanski N; Brooks DJ
Brain; 2000 Feb; 123 ( Pt 2)():340-52. PubMed ID: 10648441
[TBL] [Abstract][Full Text] [Related]
45. Parkinson's disease is associated with hippocampal atrophy.
Camicioli R; Moore MM; Kinney A; Corbridge E; Glassberg K; Kaye JA
Mov Disord; 2003 Jul; 18(7):784-90. PubMed ID: 12815657
[TBL] [Abstract][Full Text] [Related]
46.
Higashi T; Nishii R; Kagawa S; Kishibe Y; Takahashi M; Okina T; Suzuki N; Hasegawa H; Nagahama Y; Ishizu K; Oishi N; Kimura H; Watanabe H; Ono M; Saji H; Yamauchi H
Ann Nucl Med; 2018 Apr; 32(3):206-216. PubMed ID: 29388083
[TBL] [Abstract][Full Text] [Related]
47. Comparison of brain MRI and 18F-FDG PET in the differential diagnosis of multiple system atrophy from Parkinson's disease.
Kwon KY; Choi CG; Kim JS; Lee MC; Chung SJ
Mov Disord; 2007 Dec; 22(16):2352-8. PubMed ID: 17894342
[TBL] [Abstract][Full Text] [Related]
48. The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson's disease: correlation with 18F-flurodeoxyglucose positron-emission tomography.
Yoon RG; Kim SJ; Kim HS; Choi CG; Kim JS; Oh J; Chung SJ; Lee CS
Neurosci Lett; 2015 Jan; 584():296-301. PubMed ID: 25450142
[TBL] [Abstract][Full Text] [Related]
49. Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease.
Pereira JB; Hall S; Jalakas M; Grothe MJ; Strandberg O; Stomrud E; Westman E; van Westen D; Hansson O
Neurobiol Dis; 2020 Jun; 139():104831. PubMed ID: 32145376
[TBL] [Abstract][Full Text] [Related]
50. FDG-PET hypometabolism is more sensitive than MRI atrophy in Parkinson's disease: A whole-brain multimodal imaging meta-analysis.
Albrecht F; Ballarini T; Neumann J; Schroeter ML
Neuroimage Clin; 2019; 21():101594. PubMed ID: 30514656
[TBL] [Abstract][Full Text] [Related]
51. Amyloid imaging in dementias with atypical presentation.
Wolk DA; Price JC; Madeira C; Saxton JA; Snitz BE; Lopez OL; Mathis CA; Klunk WE; DeKosky ST
Alzheimers Dement; 2012 Sep; 8(5):389-98. PubMed ID: 22285638
[TBL] [Abstract][Full Text] [Related]
52. Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease.
Pilotto A; Premi E; Paola Caminiti S; Presotto L; Turrone R; Alberici A; Paghera B; Borroni B; Padovani A; Perani D
Neurology; 2018 Mar; 90(12):e1029-e1037. PubMed ID: 29453242
[TBL] [Abstract][Full Text] [Related]
53. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
Frings L; Hellwig S; Bormann T; Spehl TS; Buchert R; Meyer PT
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1442-1448. PubMed ID: 29546632
[TBL] [Abstract][Full Text] [Related]
54. Longitudinal brain atrophy distribution in advanced Parkinson's disease: What makes the difference in "cognitive status" converters?
Gorges M; Kunz MS; Müller HP; Liepelt-Scarfone I; Storch A; Dodel R; Hilker-Roggendorf R; ; Berg D; Kalbe E; Braak H; Del Tredici K; Baudrexel S; Huppertz HJ; Kassubek J
Hum Brain Mapp; 2020 Apr; 41(6):1416-1434. PubMed ID: 31789477
[TBL] [Abstract][Full Text] [Related]
55. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
56. Parkinson's disease dementia: clinical correlates of brain spect perfusion and treatment.
Kramberger MG; Stukovnik V; Cus A; Repovs G; Tomse P; Meglic NP; Garasević Z; Jensterle J; Pirtosek Z
Psychiatr Danub; 2010 Sep; 22(3):446-9. PubMed ID: 20856190
[TBL] [Abstract][Full Text] [Related]
57. Three presenile patients in which neuropsychological and neuroimaging examinations suggest possible progression to dementia with Lewy bodies.
Ota K; Iseki E; Murayama N; Chiba Y; Fujishiro H; Kasanuki K; Manabe Y; Arai H; Sato K
Psychogeriatrics; 2014 Mar; 14(1):72-80. PubMed ID: 24528622
[TBL] [Abstract][Full Text] [Related]
58. Syndrome-specific patterns of regional cerebral glucose metabolism in posterior cortical atrophy in comparison to dementia with Lewy bodies and Alzheimer's disease--a [F-18]-FDG pet study.
Spehl TS; Hellwig S; Amtage F; Weiller C; Bormann T; Weber WA; Hüll M; Meyer PT; Frings L
J Neuroimaging; 2015; 25(2):281-288. PubMed ID: 24593796
[TBL] [Abstract][Full Text] [Related]
59. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
[TBL] [Abstract][Full Text] [Related]
60. In Vivo
Tang Y; Li L; Hu T; Jiao F; Han L; Li S; Xu Z; Fan Y; Sun Y; Liu F; Yen TC; Zuo C; Wang J
Mov Disord; 2023 Jan; 38(1):147-152. PubMed ID: 36368769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
